Sign in or Register   Sign in or Register
  |  

Mouse Anti-CYP2C9 Recombinant Antibody (CBLC-LY-020) (CBMAB-C9419-LY)

This product is antibody recognizes CYP2C9. The antibody CBLC-LY-020 immunoassay techniques such as: WB.
See all CYP2C9 antibodies

Summary

Host Animal
Mouse
Specificity
Human
Clone
CBLC-LY-020
Antibody Isotype
IgM
Application
WB

Basic Information

Specificity
Human
Antibody Isotype
IgM
Clonality
Monoclonal
Application Notes
The COA includes recommended starting dilutions, optimal dilutions should be determined by the end user.

Formulations & Storage [For reference only, actual COA shall prevail!]

Format
Liquid
Preservative
0.09% sodium azide
Storage
Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freezethaw cycles.

Target

Full Name
Cytochrome P450 Family 2 Subfamily C Member 9
Introduction
CYP2C9 (Cytochrome P450 Family 2 Subfamily C Member 9) is a Protein Coding gene. Diseases associated with CYP2C9 include Coumarin Resistance and Oral Antidiabetic Drugs Toxicity Or Dose Selection. Among its related pathways are Gefitinib Pathway, Pharmacokinetics and Statin Pathway - Generalized, Pharmacokinetics. Gene Ontology (GO) annotations related to this gene include oxidoreductase activity and heme binding.
An important paralog of this gene is CYP2C19.
Entrez Gene ID
1559
UniProt ID
P11712
Alternative Names
Cytochrome P450 Family 2 Subfamily C Member 9; Cytochrome P450, Family 2, Subfamily C, Polypeptide 9; Cytochrome P450 PB-1; Cytochrome P-450MP; CYP2C10; CYPIIC9; Cytochrome P450, Subfamily IIC (Mephenytoin 4-Hydroxylase), Polypeptide 9; Cytochrome P-450 S-Mephenytoin 4-Hydroxylase; Flavoprotein-Linked Monooxygenase; (R)-Limonene 6-Monooxygenase; (S)-Limonene 6-Monooxygenase; (S)-Limonene 7-Monooxygenase; S-Mephenytoin 4-Hydroxylase; Cholesterol 25-Hydroxylase; Microsomal Monooxygenase;
Function
A cytochrome P450 monooxygenase involved in the metabolism of various endogenous substrates, including fatty acids and steroids (PubMed:7574697, PubMed:9866708, PubMed:9435160, PubMed:12865317, PubMed:15766564, PubMed:19965576, PubMed:21576599).

Mechanistically, uses molecular oxygen inserting one oxygen atom into a substrate, and reducing the second into a water molecule, with two electrons provided by NADPH via cytochrome P450 reductase (NADPH--hemoprotein reductase) (PubMed:7574697, PubMed:9866708, PubMed:9435160, PubMed:12865317, PubMed:15766564, PubMed:19965576, PubMed:21576599).

Catalyzes the epoxidation of double bonds of polyunsaturated fatty acids (PUFA) (PubMed:7574697, PubMed:15766564, PubMed:19965576, PubMed:9866708).

Catalyzes the hydroxylation of carbon-hydrogen bonds. Metabolizes cholesterol toward 25-hydroxycholesterol, a physiological regulator of cellular cholesterol homeostasis (PubMed:21576599).

Exhibits low catalytic activity for the formation of catechol estrogens from 17beta-estradiol (E2) and estrone (E1), namely 2-hydroxy E1 and E2 (PubMed:12865317).

Catalyzes bisallylic hydroxylation and hydroxylation with double-bond migration of polyunsaturated fatty acids (PUFA) (PubMed:9866708, PubMed:9435160).

Also metabolizes plant monoterpenes such as limonene. Oxygenates (R)- and (S)-limonene to produce carveol and perillyl alcohol (PubMed:11950794).

Contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenytoin, tolbutamide and losartan (PubMed:25994031).
Biological Process
Cellular amide metabolic process Source: BHF-UCL
Cholesterol metabolic process Source: UniProtKB-UniPathway
Drug catabolic process Source: BHF-UCL
Drug metabolic process Source: BHF-UCL
Epoxygenase P450 pathway Source: UniProtKB
Estrogen metabolic process Source: UniProtKB
Exogenous drug catabolic process Source: BHF-UCL
Icosanoid biosynthetic process Source: UniProtKB
Long-chain fatty acid biosynthetic process Source: Reactome
Monocarboxylic acid metabolic process Source: BHF-UCL
Monoterpenoid metabolic process Source: BHF-UCL
Omega-hydroxylase P450 pathway Source: Reactome
Organic acid metabolic process Source: GO_Central
Oxidative demethylation Source: BHF-UCL
Steroid metabolic process Source: BHF-UCL
Urea metabolic process Source: BHF-UCL
Xenobiotic metabolic process Source: GO_Central
Cellular Location
Endoplasmic reticulum membrane; Microsome membrane

Sangkuhl, K., Claudio‐Campos, K., Cavallari, L. H., Agundez, J. A., Whirl‐Carrillo, M., Duconge, J., ... & Gaedigk, A. (2021). PharmVar GeneFocus: CYP2C9. Clinical Pharmacology & Therapeutics, 110(3), 662-676.

Amorosi, C. J., Chiasson, M. A., McDonald, M. G., Wong, L. H., Sitko, K. A., Boyle, G., ... & Dunham, M. J. (2021). Massively parallel characterization of CYP2C9 variant enzyme activity and abundance. The American Journal of Human Genetics, 108(9), 1735-1751.

Chen, H., Dai, D. P., Zhou, S., Liu, J., Wang, S. H., Wu, H. L., ... & Yang, J. F. (2020). An identification and functional evaluation of a novel CYP2C9 variant CYP2C9* 62. Chemico-Biological Interactions, 327, 109168.

Theken, K. N., Lee, C. R., Gong, L., Caudle, K. E., Formea, C. M., Gaedigk, A., ... & Grosser, T. (2020). Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC) for CYP2C9 and nonsteroidal anti‐inflammatory drugs. Clinical Pharmacology & Therapeutics, 108(2), 191-200.

Monostory, K., Nagy, A., Tóth, K., Bűdi, T., Kiss, Á., Déri, M., & Csukly, G. (2019). Relevance of CYP2C9 function in valproate therapy. Current neuropharmacology, 17(1), 99-106.

Louet, M., Labbé, C. M., Fagnen, C., Aono, C. M., Homem-de-Mello, P., Villoutreix, B. O., & Miteva, M. A. (2018). Insights into molecular mechanisms of drug metabolism dysfunction of human CYP2C9* 30. PloS one, 13(5), e0197249.

Silvado, C. E., Terra, V. C., & Twardowschy, C. A. (2018). CYP2C9 polymorphisms in epilepsy: influence on phenytoin treatment. Pharmacogenomics and Personalized Medicine, 11, 51.

Flora, D. R., Rettie, A. E., Brundage, R. C., & Tracy, T. S. (2017). CYP2C9 genotype‐dependent warfarin pharmacokinetics: impact of CYP2C9 genotype on R‐and S‐warfarin and their oxidative metabolites. The Journal of Clinical Pharmacology, 57(3), 382-393.

Daly, A. K., Rettie, A. E., Fowler, D. M., & Miners, J. O. (2017). Pharmacogenomics of CYP2C9: functional and clinical considerations. Journal of personalized medicine, 8(1), 1.

Liu, R., Lyu, X., Batt, S. M., Hsu, M. H., Harbut, M. B., Vilchèze, C., ... & Wang, F. (2017). Determinants of the Inhibition of DprE1 and CYP2C9 by Antitubercular Thiophenes. Angewandte Chemie International Edition, 56(42), 13011-13015.

Ask a question We look forward to hearing from you.
0 reviews or Q&As

Purchasing FAQs
Technical FAQs

Loading...
Have you used Mouse Anti-CYP2C9 Recombinant Antibody (CBLC-LY-020)?
Submit a review and get a Coupon or an Amazon gift card. 20% off Coupon $30 eGift Card
Submit a review
Loading...
For research use only. Not intended for any clinical use.

Custom Antibody Labeling

We also offer labeled antibodies developed using our catalog antibody products and nonfluorescent conjugates (HRP, AP, Biotin, etc.) or fluorescent conjugates (Alexa Fluor, FITC, TRITC, Rhodamine, Texas Red, R-PE, APC, Qdot Probes, Pacific Dyes, etc.).

Online Inquiry

Documents

Contact us

  • Tel: (USA)
  • (UK)
  • Fax:
  • Email:

Submit A Review

Go to
Compare